Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Journal of the Korean Ophthalmological Society ; : 276-282, 2012.
Article in Korean | WPRIM | ID: wpr-9405

ABSTRACT

PURPOSE: To compare the clinical outcomes of intravitreal bevacizumab with and without posterior subtenon triamcinolone acetonide injections for macular edema with branch retinal vein occlusion. METHODS: Intravitreal bevacizumab injection (single group) or intravitreal bevacizumab injection with posterior subtenon triamcinolone acetonide injection (combined group) were performed in 30 eyes each, and intravitreal bevacizumab injection was given once a month in both groups until macular edema was in the normal range. A best corrected visual acuity and central macular thickness were measured pre- and post-injection. RESULTS: The required number of injections to achieve improved macular edema in the normal range was 2.8 +/- 0.5 times in the single group and 2.0 +/- 0.6 times in the combined group. Six months after injection, average central macular thickness decreased to 185.3 +/- 63.5 microm in the single group and to 260.0 +/- 74.6 microm in the combined group. The best corrected visual acuity (log MAR) improved from 0.71 +/- 0.63 to 0.35 +/- 0.44 in the single group and from 0.67 +/- 0.42 to 0.08 +/- 0.11 in the combined group. The number of cases in which the central macular thickness increased again within 6 months after the injections was 19 eyes in the single group and 6 eyes in the combined group. CONCLUSIONS: In macular edema with branch retinal vein occlusion, early rapid recovery of visual acuity and decrease of central macular thickness were observed due to the synergistic effect of bevacizumab and triamcinolone acetonide in combined therapy, and the recurrence frequency of macular edema was reduced by the long-term effect instilled by the long half-life of triamcinolone acetonide.


Subject(s)
Antibodies, Monoclonal, Humanized , Eye , Half-Life , Macular Edema , Recurrence , Reference Values , Retinal Vein , Retinal Vein Occlusion , Retinaldehyde , Triamcinolone , Triamcinolone Acetonide , Visual Acuity , Bevacizumab
2.
Journal of the Korean Ophthalmological Society ; : 887-892, 2011.
Article in Korean | WPRIM | ID: wpr-48925

ABSTRACT

PURPOSE: To present a case of a patient with decreased visual acuity and anterior ischemic optic neuropathy diagnosed with advanced Moyamoya disease. CASE SUMMARY: A 46-year-old woman presented sudden episodes of headache and decreased visual acuity. On her first visit, her best corrected visual acuity was 20/25 in the right eye and 20/70 in the left eye. The left eye pupil was dilated with a relative afferent papillary defect. Fundus examinations revealed disc swelling in the left eye. After being admitted, steroid pulse therapy was started and Magnetic Resonance Imaging (MRI) studies revealed Moyamoya disease. The diagnosis was confirmed via Magnetic Resonance Angiography (MRA). After steroid pulse therapy, the headaches and visual acuity improved and the patient is continuing follow-up visits at neurosurgery and ophthalmology clinics. CONCLUSIONS: Patients with Moyamoya disease may initially present symptoms and signs of anterior ischemic optic neuropathy.


Subject(s)
Female , Humans , Middle Aged , Eye , Follow-Up Studies , Headache , Magnetic Resonance Angiography , Magnetic Resonance Imaging , Moyamoya Disease , Neurosurgery , Ophthalmology , Optic Nerve Diseases , Optic Neuropathy, Ischemic , Pupil , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL